Liewen Jiang

2.3k total citations
19 papers, 503 citations indexed

About

Liewen Jiang is a scholar working on Surgery, Oncology and Cancer Research. According to data from OpenAlex, Liewen Jiang has authored 19 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 11 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Liewen Jiang's work include Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). Liewen Jiang is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). Liewen Jiang collaborates with scholars based in United States, United Kingdom and Spain. Liewen Jiang's co-authors include Camelia Gliser, Shuchi S. Pandya, Huixia Wang, Howard D. Bondell, Ahmed Amer, Daniel Gaudet, Karine Tremblay, Charles D. Meyers, Jin Chen and Bin Wu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Statistics in Medicine.

In The Last Decade

Liewen Jiang

19 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liewen Jiang United States	10	213	160	149	119	113	19	503
Kolette D. Fly United States	8	69 0.3×	179 1.1×	233 1.6×	73 0.6×	93 0.8×	15	460
Paola Coco Italy	12	159 0.7×	143 0.9×	420 2.8×	28 0.2×	98 0.9×	22	651
Isabelle Peyrottes France	18	170 0.8×	263 1.6×	263 1.8×	278 2.3×	293 2.6×	41	901
Amit Mehta United States	12	126 0.6×	183 1.1×	300 2.0×	115 1.0×	197 1.7×	18	667
Petros M. Pavlopoulos Greece	13	155 0.7×	125 0.8×	118 0.8×	155 1.3×	318 2.8×	28	653
Shuji Sumie Japan	20	457 2.1×	202 1.3×	171 1.1×	281 2.4×	161 1.4×	38	1.6k
Junichi Tomomatsu Japan	13	61 0.3×	232 1.4×	158 1.1×	38 0.3×	106 0.9×	49	431
Justine Hollyer United Kingdom	7	197 0.9×	198 1.2×	149 1.0×	225 1.9×	311 2.8×	9	652
Keiichi Honma Japan	12	155 0.7×	205 1.3×	271 1.8×	190 1.6×	175 1.5×	29	621
Joanna Gale United Kingdom	8	143 0.7×	143 0.9×	323 2.2×	86 0.7×	52 0.5×	22	641

Countries citing papers authored by Liewen Jiang

Since Specialization

Citations

This map shows the geographic impact of Liewen Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liewen Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liewen Jiang more than expected).

Fields of papers citing papers by Liewen Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liewen Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liewen Jiang. The network helps show where Liewen Jiang may publish in the future.

Co-authorship network of co-authors of Liewen Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Liewen Jiang. A scholar is included among the top collaborators of Liewen Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liewen Jiang. Liewen Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Zhu, Andrew X., Teresa Macarulla, Milind Javle, et al.. (2021). Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology. 39(3_suppl). 266–266. 38 indexed citations

Abou‐Alfa, Ghassan K., Teresa Macarulla, Milind Javle, et al.. (2021). Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology. 39(15_suppl). 4069–4069. 1 indexed citations

Aguado-Fraile, Elia, Anna M. Tassinari, Yuko Ishii, et al.. (2021). Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma. Future Oncology. 17(16). 2057–2074. 16 indexed citations

Abou‐Alfa, Ghassan K., Andrew X. Zhu, Teresa Macarulla, et al.. (2020). IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study.. Journal of Clinical Oncology. 38(15_suppl). 4576–4576. 19 indexed citations

Fan, Bin, Ghassan K. Abou‐Alfa, Andrew X. Zhu, et al.. (2020). Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study.. Journal of Clinical Oncology. 38(4_suppl). 539–539. 3 indexed citations

Tap, William D., Víctor M. Villalobos, Gregory M. Coté, et al.. (2020). Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of Clinical Oncology. 38(15). 1693–1701. 109 indexed citations

Fan, Bin, Ingo K. Mellinghoff, Patrick Y. Wen, et al.. (2019). Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. Investigational New Drugs. 38(2). 433–444. 71 indexed citations

Aguado-Fraile, Elia, Sung Choe, Camelia Gliser, et al.. (2019). Abstract 2275: Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma. Cancer Research. 79(13_Supplement). 2275–2275. 2 indexed citations

Abou‐Alfa, Ghassan K., Juan W. Valle, Robin Kate Kelley, et al.. (2018). ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 36(4_suppl). TPS545–TPS545. 6 indexed citations

10.

Fan, Bin, Ingo K. Mellinghoff, Patrick Y. Wen, et al.. (2018). Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with IDH1-mutant advanced solid tumors from a phase 1 study.. Journal of Clinical Oncology. 36(15_suppl). 2577–2577. 2 indexed citations

11.

Ishii, Yuko, Carlie Sigel, Maeve A. Lowery, et al.. (2018). Abstract A071: AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma. Molecular Cancer Therapeutics. 17(1_Supplement). A071–A071. 7 indexed citations

12.

Lowery, Maeve A., Ghassan K. Abou‐Alfa, Juan W. Valle, et al.. (2017). ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. Journal of Clinical Oncology. 35(15_suppl). TPS4142–TPS4142. 11 indexed citations

13.

Lowery, Maeve A., Ghassan K. Abou‐Alfa, Howard A. Burris, et al.. (2017). Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.. Journal of Clinical Oncology. 35(15_suppl). 4015–4015. 73 indexed citations

14.

Li, Lingling, Shijie Tang, & Liewen Jiang. (2017). On an enhanced rank‐preserving structural failure time model to handle treatment switch, crossover, and dropout. Statistics in Medicine. 36(10). 1532–1547. 5 indexed citations

15.

Fan, Bin, Lipika Goyal, Maeve A. Lowery, et al.. (2017). Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 4082–4082. 2 indexed citations

16.

Fowler, Nathan, Joseph Pearlberg, Les Brail, et al.. (2016). FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen.. Journal of Clinical Oncology. 34(15_suppl). TPS7578–TPS7578. 4 indexed citations

17.

Meyers, Charles D., Karine Tremblay, Ahmed Amer, et al.. (2015). Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids in Health and Disease. 14(1). 8–8. 83 indexed citations

18.

Jiang, Liewen, Howard D. Bondell, & Huixia Wang. (2013). Interquantile shrinkage and variable selection in quantile regression. Computational Statistics & Data Analysis. 69. 208–219. 29 indexed citations

19.

Jiang, Liewen, Huixia Wang, & Howard D. Bondell. (2013). Interquantile Shrinkage in Regression Models. Journal of Computational and Graphical Statistics. 22(4). 970–986. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact